Antiresorptive Therapy to Reduce Fracture Risk and Effects on Dental Implant Outcomes in Patients With Osteoporosis: A Systematic Review and Osteonecrosis of the Jaw Taskforce Consensus Statement.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ali Dalal S, Khan Aliya A, Morrison Archibald, Tetradis Sotirios, Mirza Reza D, El Rabbany Mohamed, Abrahamsen Bo, Aghaloo Tara L, Al-Alwani Hatim, Al-Dabagh Rana, Anastasilakis Athanasios D, Bhandari Mohit, Body Jean-Jacques, Brandi Maria Luisa, Brignardello-Petersen Romina, Brown Jacques P, Cheung Angela M, Compston Juliet, Cooper Cyrus, Diez-Perez Adolfo, Ferrari Serge L, Guyatt Gordon, Hanley David, Harvey Nicholas C, Josse Robert G, Kendler David L, Khan Sarah, Kim Sandra, Langdahl Bente L, Magopoulos Christos, Masri Basel K, Morgan Sarah L, Morin Suzanne N, Napoli Nicola, Obermayer-Pietsch Barbara, Palermo Andrea, Pepe Jessica, Peters Edmund, Pierroz Dominique D, Rizzoli Rene, Saunders Deborah P, Stanford Clark M, Sulimani Riad, Taguchi Akira, Tanaka Sakae, Watts Nelson B, Zamudio Joile, Zillikens M Carola, Ruggiero Salvatore L
Аннотация
METHODS: The International ONJ Taskforce conducted a systematic review of the literature and evaluated the outcomes of implant placement in individuals with osteoporosis receiving antiresorptive therapy.
RESULTS: The data were reviewed by the International Taskforce, and consensus was achieved on the following GRADEd recommendation. In patients with osteoporosis on antiresorptive therapy, the Taskforce suggests that antiresorptive therapy does not need to be stopped prior to proceeding with dental implant (weak recommendation, very low-quality evidence). Long-term bisphosphonate use maybe associated with a small increase in the risk of MRONJ (3 cases per 1000 patients; adjusted hazard ratio: 4.09, 95% CI: 2.75-6.09, P < .001, moderate certainty).
CONCLUSION: Current evidence does not suggest an association between antiresorptive therapy in patients with osteoporosis and dental implant failure. Implants may be safely placed in the presence of concomitant use of bisphosphonates or denosumab in patients with osteoporosis with no evidence of an increased risk of implant failure/compromise.